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Proteins of the 4.1 family are characteristic of eumetazoan organisms. Invertebrates contain single 4.1 genes
and the Drosophila model suggests that 4.1 is essential for animal life. Vertebrates have four paralogues,
known as 4.1R, 4.1N, 4.1G and 4.1B, which are additionally duplicated in the ray-ﬁnned ﬁsh. Protein 4.1R
was the ﬁrst to be discovered: it is a major mammalian erythrocyte cytoskeletal protein, essential to the
mechanochemical properties of red cell membranes because it promotes the interaction between spectrin
and actin in the membrane cytoskeleton. 4.1R also binds certain phospholipids and is required for the stable
cell surface accumulation of a number of erythrocyte transmembrane proteins that span multiple functional
classes; these include cell adhesion molecules, transporters and a chemokine receptor. The vertebrate 4.1
proteins are expressed in most tissues, and they are required for the correct cell surface accumulation of a
very wide variety of membrane proteins including G-Protein coupled receptors, voltage-gated and
ligand-gated channels, as well as the classes identiﬁed in erythrocytes. Indeed, such large numbers of protein
interactions have been mapped for mammalian 4.1 proteins, most especially 4.1R, that it appears that they
can act as hubs for membrane protein organization. The range of critical interactions of 4.1 proteins is
reﬂected in disease relationships that include hereditary anaemias, tumour suppression, control of heartbeat
and nervous system function. The 4.1 proteins are deﬁned by their domain structure: apart from the spectrin/
actin-binding domain they have FERM and FERM-adjacent domains and a unique C-terminal domain.
Both the FERM and C-terminal domains can bind transmembrane proteins, thus they have the potential to
be cross-linkers for membrane proteins. The activity of the FERM domain is subject to multiple modes of
regulation via binding of regulatory ligands, phosphorylation of the FERM associated domain and differential
mRNA splicing. Finally, the spectrum of interactions of the 4.1 proteins overlaps with that of another
membrane-cytoskeleton linker, ankyrin. Both ankyrin and 4.1 link to the actin cytoskeleton via spectrin,
and we hypothesize that differential regulation of 4.1 proteins and ankyrins allows highly selective
control of cell surface protein accumulation and, hence, function. This article is part of a Special Issue
entitled: Reciprocal inﬂuences between cell cytoskeleton and membrane channels, receptors and trans-
porters. Guest Editor: Jean Claude Hervé© 2013 Elsevier B.V. All rights reserved.Contents
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This paper focuses on a group of proteins descended from ancestors
that appear to have emerged early in animal evolution as part of
a mechanism to allow tissues to form and to function in the context of
whole organism physiology.
During the evolution of animals from simpler ancestors (those were
probably colonial protists) new adaptations emerged that resulted in
differentiated cells forming selective cell–cell interactions, leading toFig. 1. Domain structure of 4.1 proteins. (A) Overall domain structure of a canonical verteb
domain; SAB, spectrin–actin binding domain; CTD, C-terminal domain. (B) Cartoon repre
indicated (A, B, C). (C) Space ﬁlling model of the FERM domain showing binding sites for
(C) and (B) represent the same sequences.formation of tissues. Further adaptations allowed formation of signalling
complexes positioned at points on cell surfaces to receive or send signals.
Consequently, animal cell plasma membranes, far from being simply
populated by transmembrane proteins ﬂoating like icebergs in a sea of
phospholipids, as envisaged in simple cartoon representations of the
ﬂuidmosaicmodel [e.g. 1], have a very high degree ofmolecule-scale or-
ganization that allows protein–protein complexes to form and turn over.
With the evolution of mammals, the specialisation of cell types
has been taken to an extreme with, for example, the advent of therate 4.1, showing major regions of interaction and regulation. Key: FA, FERM adjacent
sentation of the fold of the FERM domain taken from PDB:1GG3. The three lobes are
transmembrane proteins Band 3 (B3), glycophorin C (GpC) and p55. The colours in
607A.J. Baines et al. / Biochimica et Biophysica Acta 1838 (2014) 605–619non-nucleated mammalian red blood cell. These and other adaptations
of animal life seem to require a number of proteins that emerged during
eumetazoan evolution.
One such protein is known as 4.1. It is a membrane-cytoskeleton
cross-linker and adaptor that can bridge between cytoplasmic spectrin–
actin ﬁlament complexes, and a wide variety of transmembrane proteins
(Fig. 1A); further components of such complexes include other adaptor
proteins such as membrane-associated guanylate kinases.
We explore here the nature of the 4.1 proteins, their interactions
and regulation, and how their functions are reﬂected in the physiology
of animals.
2. The protein 4.1 family: genes, proteins and domains
2.1. Discovery and general organization
Protein 4.1 was discovered in human red blood cells. Its name
derives from its identiﬁcation as a particular band on an SDS gel of
erythrocyte membranes (“band 4.1 protein”) [2]. Subsequently, gene
cloning and genomics identiﬁed a total of four paralogues in vertebrates
(with additional duplicates in ray-ﬁnned ﬁsh) [3]; other animals have
single copies of 4.1 genes [4,5].
To distinguish the different paralogues, the proteins are now named
4.1R (the prototypical protein found ﬁrst in red blood cells), 4.1N, 4.1G
and 4.1B. Although the latter three were initially identiﬁed in neurons,
generally, and brain, all four are relatively ubiquitously expressed.
The corresponding genes are, respectively, EPB41, EPB41L1, EPB41L2
and EPB41L3 (see Table 1).
All 4.1 proteins, from the simplest invertebrates to mammals, have
two common functional domains: a FERM domain and a C-terminal
domain (CTD) that is unique to this group of proteins and deﬁne it
(Fig. 1A, and Table 2). Additional exons characterise particular groups
of animals in both invertebrates and vertebrates, with a particular gain
of function in higher animals through the acquisition of a spectrin–
actin binding domain (SAB) [5].
In mammals, the FERM domain is preceded on the N-terminal side
by a variably spliced headpiece (also known as the U1 region) [6].
Splicing of the headpiece generates the two most abundant isoforms
of 4.1R (apparent molecular mass on SDS gels 120–135 kDa and
80 kDa). However, the apparent molecular masses of 4.1R isoforms
on SDS gels differ from the true masses derived from the sequence,
and the true masses vary further because of differential splicing ofTable 1
Genes encoding 4.1 proteins and their corresponding phenotypes.
Vertebrates
Protein Gene Organism Uniprot Physiological phenotype
4.1R EPB41 Human P11171 Hereditary elliptocytosis
Mouse P48193 Hereditary spherocytosis; fragile/misshapen ce
Heart: bradycardia, long QT, prolonged action
Learning and memory defects.
Defective wound healing.
Disorganisation of gastric glands.
Defective Ca2+ absorption.
Elevated humoral response to immunization.
4.1N EPB41L1 Human Q9H4G0 Nonsyndromic intellectual disability
Mouse Q9Z2H5
4.1G EPB41L2 Human O43491
Mouse O70318 Male infertility
4.1B EPB41L3 Human Q9Y2J2 Suppression of lung, meningioma, beta cell, br
Mouse Q9WV92 Impaired gait and motility. Stabilisation of para
Invertebrates
Coracle Cora Fruitﬂy Q9V8R9 Recessive embryonic lethality resulting from fail
adult somaticmuscle development;maintenanc
tube size, open tracheal system; establishment o
FRM-1 frm-1 C. elegans G5EEP9 Delayed hatching/temperature sensitive sterili
4.1 Leech Impaired axon regeneration.small exons. Based on the amino acid sequence, 80 kDa forms are in
the region of 66 kDa (e.g. Uniprot:P11171-4), and the 120/135 kDa
isoforms are approximately 97 kDa (e.g. Uniprot:P11171-1).
Between the FERMdomain and the spectrin–actin binding (SAB) do-
main lies a further variably spliced domainmostly of unknown function,
and known as U2 [7,8]. Within this is a FERM-adjacent domain (FA)
which contains regulatory phosphorylation sites [9]. A third variably
spliced region (U3) lies between the SAB and C-terminal domains [7,8].
Of all these domains, only the FERM structure is known at atomic
resolution [10]. The C-terminal domain is probably folded [11], but
as yet no successful structural analysis has been reported. Structures
of the other domains are unknown, although the headpiece [12] and
SAB domains [9,13] are probably largely intrinsically unstructured.
2.2. The FERM domain
2.2.1. Structure
The FERM domain was discovered by limited proteolysis of erythro-
cyte 4.1R [14]. A 30 kDa proteolytic fragment was found to bind erythro-
cyte membranes, via both protein and phospholipid sites [14–16].
Subsequent sequence comparison revealed similarity with a similar
sized domain in the ERM proteins (ezrin, radixin and moesin), hence
the name FERM (four-point-one, ERM) [17]. It is now clear that the
FERM domain is widely spread in eukaryotic evolution, and appears
to be a genetically mobile module that has been incorporated in a wide
variety of genes [see e.g. 18]. It is very highly conserved among the 4.1
proteins: about 75% amino acid sequence identity between all paralogues
in any mammalian species; the FERM domains of human 4.1R and fruit
ﬂy 4.1 (coracle) are about 65% identical.
The atomic structure of the human 4.1R and mouse 4.1B FERM do-
mains have been determined by x-ray crystallography (Fig. 1B and C)
[10,19]. They show a common three-lobed structure which is, in
effect, a supra-domain [20]; in other words the folded structure is itself
made up of three separately folded lobes. The N-terminal lobe (lobe A)
has a fold analogous to ubiquitin. The central lobe (lobe B) has an
α-helical fold like acyl-CoA binding protein. The C-terminal lobe (lobe
C) has a fold like a pleckstrin homology domain [10]. This overall folding
structure is conserved throughout known FERM domains, even though
the level of sequence conservation is extremely low [18].
The lobes of the FERM domain are associated with ligand binding
activities. In the case of 4.1R, Lobe A binds the erythrocyte anion
exchanger and the rhesus complex proteins Rh; lobe B binds theReference
[71,171,172]
lls.
potential.
[37,77,78,80,82,84,102]
[173]
[103]
east, ovarian, prostate cancer progression/metastasis. [86,87,89,95,174,175]
nodes and juxtaparanodes; maintenance of axonal domains [105,106]
ure in dorsal closure. Required in embryonic morphogenesis;
e of imaginal disc-derivedwing hair orientation; regulation of
f glial blood–brain barrier.
[4,176,177]
ty (tm4168) [178]
[179]
Table 2
Domain and structure database cross references.
Domain PFAM Interpro PDB
FERM PF09379 (Lobe A)
PF00373 (Lobe B)
PF09380 (Lobe C)
IPR000299
(Whole domain)
IPR018979 (Lobe A)
IPR019748 (Lobe B)
IPR018980 (Lobe C)
4.1R: 1GG3,
2RQ1
3QIJ
4.1B: 2HE7, 3BIN
(structure with cytoplasmic
domain of TSLC1 bound)
FA PF08736 IPR014847
SAB PF04382 IPR007477
CTD PF05902 IPR008379
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lobe C also binds the cell adhesion molecule CD44 and phospholipid
phosphatidylserine [21–24]. Themalaria parasite Plasmodium falciparum
secretes a protein named Mesa which binds lobe C during the intra-
erythrocytic phase of its life cycle [25]. Lobes A and C together form a
binding site for the cytoskeletal adapter protein p55 [26] and the lipid
phosphatidylinositol-4,5-bisphosphate (PIP2) [27].
2.2.2. Regulation
The FERM domain represents a point where numerous forms of
regulation converge on the interaction of 4.1 with membrane-bound
ligands. Regulation has been extensively characterised for 4.1R; much
less is known about the regulation of the other three 4.1 proteins.
Ser-312 and Ser-331 in the 4.1R FA domain are substrates for
protein kinase C; their phosphorylation weakens the interaction of
lobe B with glycophorin C, Duffy and XK [28], and this is associated
with weakening membrane mechanical stability [29].
PIP2 promotes binding of glycophorin C, but inhibits binding
of the erythrocyte anion exchanger [27]. As with the ERM proteins,
PIP2 causes a conformational change in the FERM domain, although
the atomic structure of a 4.1 FERM domain with bound PIP2 has not
been determined thus far.
The presence of the 4.1 headpiece weakens the interaction with
glycophorin C [12]. The headpiece also contains a Ca2+/calmodulin
binding site [12,30,31]. Binding of Ca2+/calmodulin to the headpiece
completely inhibits the binding of 4.1R to glycophorin C, and greatly
inhibits binding to the erythrocyte anion exchanger [31].
Ca2+/calmodulin is also known to control erythrocyte mechanical
properties: calmodulin in the presence of physiological Ca2+ concentra-
tions (but not in its absence) reduces membrane mechanical stability
[32]. 4.1R seems to be one of the effector proteins for Ca2+/calmodulin
function in this regard, even though the major (80 kDa) isoforms of
4.1R in the erythrocyte lack the headpiece. However, Ca2+/calmodulin
and apo-calmodulin also bind to the FERM domain. There are two
separate binding sites: a Ca2+ -dependent one (PDB:1GG3, residues
181–197) linking the end of lobe B to the ﬁrst β-strand of lobe C and
a Ca2+-independent one (PDB:1GG3, residues 264–280) located in
the C-terminal α-helix of lobe C [33]. The Ca2+ bound form inhibits
interaction with the anion exchanger [23,33].
2.3. The C-terminal domain
Like the FERM domain, the C-terminal domain was ﬁrst discovered
by its resistance to limited proteolysis of erythrocyte 4.1R. The appar-
ent molecular mass of the fragments is 22/24 kDa, although as with
whole 4.1R the true mass differs from that reported by SDS gels:
mass spectrometry conﬁrms prediction from sequence that the
molecular mass is 17 kDa. [11,14]. No high resolution structure has
been determined yet, but protease resistance, as well as its globular
properties indicate it is folded. It is highly conserved in evolution,
and, because it is unique to 4.1 proteins, effectively deﬁnes them [11].
The CTD binds to a number of membrane proteins. For example,
the cytoplasmic C-terminal regions of glutamate receptors GluR1and GluR3 interact with 4.1 CTD [34,35]. A similar interaction is
reported in fruit ﬂies where the CTD of coracle interacts with GluRIIA,
-B and -D, which are homologouswithmammalian ionotropic glutamate
receptors [36]. The plasma membrane Ca2+ pump, PMCA1b, interacts
with the CTD via its cytoplasmic C-terminal region [37].
The CTD alsomediates interactionwith certain cytoplasmic proteins,
including NuMA, a protein associated with mitotic spindles [38] and
with FKBP13 [39,40].
2.4. Developmental regulation of 4.1 by mRNA splicing
22 exons code for the sequence of 4.1R. Of these approximately
half can be subject to differential mRNA splicing [e.g. 7,41,42]. A
similar scale of splice variation is noted with the other 4.1 paralogues
[8]. The main consequences are as follows.
Since the headpiece has such a signiﬁcant effect on FERM domain
interaction, and confers a level of Ca2+/calmodulin regulation on
FERM activities, it is important to note that splicing of this region is
developmentally regulated. The headpiece is encoded by exons 2 and
the beginning of exon 4; exon2 is variably spliced. During erythropoiesis,
early-stage isoforms of 4.1R include exon 2 and therefore have an ex-
tended headpiece [43,6]. During terminal differentiation the headpiece
is lost [44].
The functional signiﬁcance of the headpiece has not yet been
evaluated fully in the other 4.1 proteins. For example, in 4.1G the head-
piece is encoded by two exons, one of which contains a calmodulin
binding sequence [8,12,45].
Further functional variation comes from differential splicing of the
SAB. This is comprised of exons 16 and 17 in vertebrate 4.1 proteins,
each of which can be differentially spliced [44,46]. Exon 17 alone can
bind spectrin and actin, but high afﬁnity binding requires both exons
[47,48].
Moreover, during erythropoiesis a wide range of splice variants of
4.1R are produced. Direct analysis by RT-PCR of full-length splice
variants revealed no less than sevenmajor and 11minor splice variants
[43]. Exon 16 is tightly regulated such that it is excluded in early
erythroid progenitor cells but efﬁciently included in late erythroblasts
[49,50]. The range of variation includes splicing in both FERM and CTD
regions, indicating that, in addition to regulation by factors such as
phosphorylation, calmodulin and PIP2, post-transcriptional mecha-
nisms contribute to regulation of 4.1R-membrane protein interaction.
Exon 5 in the FERM domain encodes both the AE1 binding site and a
site for binding of protein p55: this too can be differentially spliced
[26,41,43]. Additional, tissue-speciﬁc splicing generates variation in
the U3 region in epithelia where exon 17A is muscle speciﬁc and exon
17B is differentially spliced during epithelial development [51].
3. Structural organization at the membrane
3.1. 4.1 function independent of high afﬁnity spectrin–actin binding
4.1 proteins are often considered as spectrin and actin binding
proteins, because of the importance of this activity to erythrocyte
membrane properties [47,48]. However, it is important to note that
the fruitﬂy 4.1 protein coracle does not have a spectrin–actin binding
domain [4], and this applies to other simple invertebrates [52]. There-
fore the activities of 4.1 proteins that evolved earliest are independent
of spectrin–actin binding.
The SAB of vertebrate 4.1 proteins can be differentially spliced
[6,7]. Indeed, analysis of the expression pattern of the SAB of 4.1R
indicates that the full SAB (comprised of exons 16 and 17 together)
is relatively selectively expressed. In erythropoiesis, for instance,
expression of exon 16 of 4.1R only occurs late in the process [53,54].
Thus, high afﬁnity spectrin–actin binding is probably only required
at the point when the erythrocyte membrane cytoskeleton complex
assembles.
609A.J. Baines et al. / Biochimica et Biophysica Acta 1838 (2014) 605–619Even in tissues where it might be expected that the mechanical
stabilisation of membranes by SAB activity would be essential, exons
16 and 17 are not constitutively expressed. For example, comprehen-
sive analysis of cDNA sequences from human andmouse heart revealed
that exon 16 could be differentially spliced from 4.1R [55]; evidently,
high afﬁnity spectrin–actin binding was not a feature of all 4.1R splice
variants.
A further consideration is that the SAB of 4.1N does not appear to
encode a high afﬁnity spectrin–actin binding activity. Gimm and
co-workers [13] analysed the activities of the SAB domains of all
four human 4.1 proteins, and found that 4.1R, 4.1G and 4.1B could
all promote cross-linking of spectrin tetramers and actin into a gel. 4.1N
was the exception and showed no such activity. It would appear that
the SAB of 4.1N has lost this activity in evolution. Alternative residual
or newly evolved activities of 4.1N SAB are not known.
All these considerations indicate that the 4.1 proteins of all animals
probably have functions that are dictated by the membrane-interactive
domains (i.e. the FERM domain and CTD). Even if the erythrocyte
paradigm indicates that spectrin–actin binding is critical in certain cell
or developmental situations, the common activity of 4.1 proteins is
their interaction with multiple membrane proteins and their assembly
into macromolecular complexes.
3.2. The 4.1-spectrin–F-actin interaction
What we know about the 4.1-spectrin–F-actin interaction at the
plasma membrane mostly comes from studies on the erythrocyte.
In the erythrocyte model, 4.1R is linked to a short ﬁlament of F-
actin that contains 12–17 monomers and has a length approximately
equivalent to a single tropomyosin molecule [56,57] (Fig. 2A). The
minus end of the F-actin is capped by tropomodulin [58], and the plus
end by adducin–spectrin [59,60] or 4.1R-spectrin complexes [61].
The binding site for the 4.1 SAB on spectrin is in the N-terminal
CH1 and CH2 domains of the actin-binding site of β-spectrin [62].
CH1 and CH2 also bind PIP2, and this regulates spectrin-4.1 inter-
action [62]. The SAB also appears to bind tropomyosin [63].
Stoichiometries of actin and 4.1R in red cell membranes suggest
that there should be 5–7 4.1R molecules per actin ﬁlament, and the
same number of spectrin molecules [56]. Spectrin itself can bind to
lipids [62,64–67] so that the whole complex is closely associated with
the membrane. Thus, 4.1R has the potential to gather together multiple
transmembrane proteins at F-actin–spectrin cytoskeleton junction
points (Fig. 2B). In the erythrocyte these junctions occur all over the
cell surface connected by the spectrin tetramer lattice [57,68].
4. Functional interaction of 4.1R with membrane proteins
4.1. Physiological and disease conditions
Table 1 shows the phenotypes that have been associated with
different 4.1 genes in mouse, man and invertebrates. The main con-
clusions are discussed in the following sections.
4.1.1. Anaemias
Early indications of the physiological requirement for 4.1R function
came from the analyses of the human hereditary anaemia elliptocytosis
(HE) [69,70]. Several different mutations in the human EPB41 gene
have been described, although homozygous cases, which show
the most extreme phenotype, are extremely rare. About 5% of cases of
HE result from quantitative deﬁciency of 4.1R, or defects in its activity
[71,72]. Activity defects are best described in relation to mutations
in the SAB domain, which lead to decreased mechanical stability of
the cell membrane. This weakness can be reversed by addition of
recombinant SAB domain to isolated red cell membranes (ghosts),
indicating that the membrane interactions of 4.1R are not essential for
the mechanical properties of the cell [48].However, some elliptocytoses reveal an additional role for 4.1R.
In quantitative deﬁciency of 4.1R, various membrane proteins are
lost or signiﬁcantly reduced. Glycophorin C, CD44, CD47 are among
these [73–75]. A peripheral protein, membrane associated guanyate
kinase (MAGUK), p55 (MPP1) is also lost [76]. Thus, a signiﬁcant
role for 4.1R emerges in relation to correct accumulation of various
membrane proteins.4.1.2. The broad phenotype of 4.1R knockout mice
A strain of knockout mice has been made and is well characterised
[77,78]. This has the ﬁrst two initiation codons (AUG1 and AUG2)
deleted. Since these two initiation codons are required for expression
of the two forms of 4.1R (120/135 kDa and 80 kDa) that are expressed
at various stages of erythropoiesis, the entire red blood cell lineage
of these animals lacks 4.1R. Nevertheless, they can still produce
a third isoform of 4.1R from AUG3 in certain tissues: this isoform
is initiated in exon 8, and yields truncated forms (50–65 kDa)
that lack lobe A and most of lobe B of the FERM domain [43,79],
see also [80].
Aswith human EPB41mutations, themice are very anaemic [77,78].
Depending on strain background, this can reach approximately 30%
reticulocytosis. Nevertheless, themice are viable, do not have a substan-
tially reduced lifespan, and can be bred as homozygotes.
The erythrocytes are mechanically weak and shed membrane,
giving a comparatively spherocytic phenotype [77]. As with human
red cells, some membrane proteins are lost or reduced in the mem-
branes, indicating a conserved role for 4.1R in this respect. Additionally,
the conformation of a portion of the anion exchanger (band 3) is altered
[24]. The activity of the Na+/H+ exchanger is misregulated [81], be-
cause there is a direct functional binding between 4.1R and the Na+/
H+ exchanger, NHE1 [82].
Beyond red cells numerous phenotypic alterations have been
observed in other tissues.
In the heart, there is a bradycardia, and the QT interval and action
potential duration are prolonged [80]. Ca2+ transients are larger and
slower to decay and there is increased sarcoplasmic reticulum Ca2+
content and frequency of Ca2+ sparks in 4.1R KO mice. In addition,
several ion transporters have altered activity: The Na+/Ca2+ exchange
current density is reduced, the transient inward current (Ito) inactiva-
tion is faster and the persistent Na+ current (INa) density is increased.
These hearts also show reduced expression of the voltage-gated Na+
channel NaV1.5 and increased expression of protein 4.1G. A relationship
between 4.1R and elements of Na+ linked signallingwas also suggested
by the quantitative colocalisation of 4.1R and the Na+/K+-ATPase and
the Na+/Ca2+ exchanger NCX1 [83].
A further phenotypic manifestation recently reported is that 4.1R
−/−mice develop hyperparathyroidism and osteoporosis due to im-
paired intestinal Ca2+ absorption [37]. This reﬂects association with
the intestinal Ca2+ pump PMCA1b. In the absence of 4.1R, PMCA1b
protein expression in small intestine was reduced to about one
quarter of thewild type level, althoughmRNAexpressionwasunchanged.
Two cytoplasmic regions of PMCA1b were found to interact with the
FERM domain of 4.1R: lobe A bound cytoplasmic loop 2 of PMCA1b;
lobe C bound to the C-terminal cytoplasmic region. Presumably 4.1R in-
teraction is required to retain PMCA1b at the enterocyte basolateral
membrane.
4.1R KO mice also display enhanced humoral response to antigens
such as nitrophenyl keyhole limpet hemocyanin (NP-KLH) [84]:
production of both IgM and IgG in response to immunization with
NP-KLH was increased. As we note below in Section 6, this derives
from altered T-cell signalling.
The mice also tend to have skin blisters that derive from poor
wound healing [85]. The migration of keratinocytes into wounds
is reduced, and this is associated with defective integrin transport to
the cell surface.
Fig. 2. 4.1 complexes in erythrocytes. (A) Organization of protein 4.1, with respect to the membrane cytoskeleton. 4.1, spectrin and actin bind together to form a junctional complex
that enables 4.1 to interact with transmembrane proteins. Another transmembrane complex is associated with ankyrin. (B) Several 4.1R molecules bind to the short stretch of actin
at the junctional complex allowing a number of 4.1 binding partners to be associated with it. The transmembrane proteins shown are those found in the erythrocyte (see text).
For simplicity, spectrin is not shown in this diagram, but 5–7 spectrin molecules also associate with each junction point, binding to actin, 4.1 and dematin (protein 4.9).
Note also that the stoichiometries of individual transmembrane proteins vary, so not all junction points will contain the full repertoire of membrane proteins shown here.
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noted in early analyses of the 4.1R KO mice [78], although molecular
correlates of this are not well established yet.4.1.3. The cancer connection
Evidence for a connection between 4.1 proteins and cancer emerged
with discovery of the DAL-1 gene (differentially expressed in adeno-
carcinoma of the lung) [86]. Sequencing of DAL-1 revealed that it was
EPB41L3, i.e. it encoded 4.1B. Loss of 4.1B (DAL-1) was linked to metas-
tasis of non-small cell lung carcinoma cells [87]. It was found to have a
direct interaction with another tumour suppressor, Tumor Suppressor
in Lung Cancer 1 (TSLC1, also known as CADM1, Igsf4, Necl2, Ra175,
Syncam, SynCam1) [88], an immunoglobulin-superfamily cell adhesion
molecule. The cytoplasmic domain of TSLC1 binds to the FERM domain
(lobe C) [19]. CADM1 is also linked with aberrant expression of 4.1B
found in invasive lesions in breast cancer, [89]. Another cell adhesion
molecule CADM4 (also known as Igsf4c, Necl4, Tsll2) is lost together
with 4.1B/DAL-1 inactivation in renal clear cell carcinoma (RCCC), the
most frequent subpopulation of renal cell carcinoma derived from
the proximal tubules [90]. The basis of loss of 4.1B expression in
both cases appeared to be hypermethylation of the promotor, again
consistent with its role as a tumour suppressor [91,90].
Loss of 4.1B (DAL-1) appeared to be an early event in pathogenesis
of meningiomas, and it had the characteristics of a tumour suppressor[92–94]. It is important in prostate cancer progression and metastasis
[95].
4.1B knockoutmice also reveal a role for this protein in regulation of
cell proliferation [96]. During pregnancy, 4.1B is greatly upregulated in
mammary epithelium, a period when epithelial cells undergo rapid
proliferation. Loss of 4.1 B in the knockout mice was associated
with increased proliferation; the presence of 4.1 B was associated
with cell cycle arrest at G1. These data point to a further functional
link between loss of 4.1B function and the pathogenesis of mam-
mary carcinomas.
Other 4.1 proteins also appear to be tumour suppressors. 4.1R
is another meningioma suppressor [97]. It is worth noting here that
CD44, a hyaluronan receptor,which requires 4.1R for correct cell surface
accumulation in red cells (Section 5.1) is also broadly expressed, and
linked to cancer progression [98]. Protein 4.1N is also reported to be
involved in the invasiveness of breast cancers [99].
There is a broader connection here to other tumour suppressors. NF2
and merlin, two well-characterised tumour suppressors, have, like 4.1
proteins, a FERM domain [100]. Loss of interaction of FERM domains
with important cell adhesion molecules appears to be a commonmech-
anism in tumour pathogenesis.
4.1.4. Relation to tissue organization: cell–cell connections
Since the interactions of cell adhesion molecules are revealed in
analysis of cancers, is there a broader role for 4.1 proteins in normal
Table 3
Some examples of transmembrane proteins that interact with 4.1 proteins in mammals.
Membrane protein 4.1 protein Reference
Ligand-gated channel
Glutamate receptor GluR1 4.1N [34,123]
Glutamate receptor GluR3 (4.1N) [35]
InsP3 receptor 4.1N [129]
α7 acetylcholine receptor 4.1N [180]
Glutamate (NMDA) receptor 4.1B [124]
Voltage-gated channel
NaV1.5 4.1R [80]
Store-operated channel
TRPC4 4.1R [132,181]
7 helix receptor
D2 and D3 4.1N [119]
mGluR1α 4.1G [120]
mGlur8 4.1B (+R,G,N) [182]
Adenosine A1 4.1G [121]
Parathyroid hormone (PTH)/PTH-related
protein receptor (PTHR)
4.1G [122]
Duffy 4.1R [24]
Solute/gas transporter
Erythrocyte/kidney anion exchanger AE1
(Band 3)
4.1R [183]
Rh (CO2/NH3) channel 4.1R [24]
Na+/Ca2+ exchanger NCX1 4.1R [80]
Na+/H+ exchanger NHE1 4.1R [82]
Membrane transport protein XK 4.1R [24]
Plasma Membrane Calcium ATPase 1b (PMCA1b) 4.1R [37]
Sarcoplasmic reticulum Ca2+-ATPase SERCA2 4.1G [83]
K-Cl co-transporter KCC2 4.1N [133]
Na+ bicarbonate cotransporter1 (NBC1) 4.1B [141]
Cell adhesion molecules
CD44 4.1R [162]
Lutheran (Lu)/BCAM 4.1R [184]
βI-integrin 4.1R [85]
β8-integrin 4.1B [185]
E-cadherin/β-catenin complex 4.1R [102]
Nectin-like molecule 1 4.1N [104]
CADM4/Nectin-Like 4 4.1G and 4.1B [90,103]
PTA-1 (CD226) 4.1G [148]
SynCAM1/TSLC1/CADM1/NECL2 4.1N and 4.1B [19,89,90,124]
Neurexin/CASPR/Paranodin 4.1B [108,186]
Other
Linker of activated T cells (LAT) 4.1R [84]
Fc γ RI 4.1G [187]
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cell–cell and cell–matrix interaction? Immunoﬂuorescence in many
cell/tissue types shows that all of the four vertebrate 4.1 proteins
are associated with membrane structures, most especially close to
regions of cell–cell and cell–matrix contact [e.g. 40,83,101]. Analyses
of knockout mice reveal extensive links to cell adhesion and tissue
organization.
In the case of 4.1R, knockout mice have impaired cell–cell con-
tact in stomach epithelium, and the gastric glands are disorganised
[102]. This probably arises from defects in the E-cadherin/β-catenin
mediated adhesion since 4.1R has been shown to bind to β-catenin
[102]. However, 4.1R may not interact with all β-catenin com-
plexes. Indeed, β-catenin and 4.1R do not coincide in cardiac inter-
calated discs, so presumably N-cadherin/β-catenin complexes do
not bind 4.1R in this tissue [83].
4.1G homozygous knockout male mice have loss of fertility
depending on strain background. These mice indicate that 4.1G plays
a role in spermatogenesis by mediating cell–cell adhesion between
spermatogenic and Sertoli cells via a cell adhesion molecule nectin-like
protein 4 [103].
A different nectin-like protein, NECL1, interacts with 4.1N in brain
[104], and we note in Table 3 a group of cell adhesion molecules such
as CASPR2, in the nervous system that interact functionally with 4.1B
[105–108].
In the case of 4.1B, again knockout mice are viable, but numerous
morphological defects are clear in various tissues. For example, in
concert with β8-integrin, 4.1B regulates morphogenesis in embryonic
heart [109]. Major roles are also revealed in the nervous system,
especially in relation to myelinated axons. The knockout mice display
mildly impaired gait and motility [106]. Morphological defects are
observed in the paranodal and juxtaparanodal regions of myelinated
axons, and destabilization of septate-like junctions in paranodes
[105,106].
The interaction of 4.1 proteins with neurexin family proteins in
the formation of septate or septate-like junctions seems to be an
ancient function since coracle, the fruitﬂy 4.1, interacts with neurexin
and this is essential in epithelial integrity mediated by septate junc-
tions [110]. We may note at this point, too, that a complex of coracle,
neurexin, gliotactin (another transmembrane protein, related to
vertebrate neuroligins) and theNa+/K+-ATPase form an interdependent
complex required for septate junction function [111]: the relationship
between 4.1 proteins and Na+-linked processes may be conserved
between ﬂy and mammals.
In summary then, there is abundant evidence for the 4.1 proteins
of vertebrates controlling cell physiology via functional interactions
with a wide variety of class of transmembrane proteins including
ion channels and exchangers, and cell adhesion molecules. In the
following sections, we discuss the molecular analysis of interactions
of the 4.1 proteins with a wide variety of membrane proteins (see
Table 3): collectively, these analyses suggest that physiological analysis
of animalmodels hasmuch yet to reveal about the contribution of these
proteins to animal life.
5. Functional interaction of 4.1 with membrane proteins
5.1. Erythrocytes
Analyses of 4.1R-deﬁcient human andmouse erythrocytes reveal the
complex array of membrane proteins that can link to 4.1R (Fig. 2B). One
of the hallmarks of 4.1R-interactive membrane proteins in erythrocytes
is that they are lost from4.1R-null cells [24,73-75,76,112]. This is because
in the process of erythropoiesis, during the ﬁnal asymmetric cell division
that releases a reticulocyte from the nuclear remnant of the erythroblast,
the interactive proteins are mis-sorted to the nuclear remnant and lost
from the erythrocyte precursor [113]. In these 4.1R deﬁcient cells nearly
all the FERM domain binding proteins are lost including the cytokinereceptor Duffy, the XK/Kell transport complex, CD44, the rhesus compo-
nent Rh and glycophorin C [24]. An exception to this is the anion ex-
changer, band 3. 4.1R knockout mouse red blood cells do not lack band
3, although access of a conformation-sensitive antibody to it is changed
[24]; the implication is that 4.1R is required for the normal conformation
of this protein. Furthermore, the proteins adducin and dematin which
provide a further route for interaction with the anion exchanger [114]
and, in addition, interact with the glucose transporter, Glut 1 [115], are
found at a lower stoichiometry on the F-actin junctional complexes in
the 4.1R deﬁcient erythrocytes. CD47 is also reported lost from human,
but not mouse, 4.1-deﬁcient erythrocytes [75].
It appears then that amajor function of 4.1R is to capturemembrane
proteins during cell differentiation and retain them at sites speciﬁed
by short actin ﬁlaments at the spectrin–actin junction point.5.2. Cardiomyocytes
Although mRNAs encoding all four 4.1 proteins are detectable
in mouse and human heart, only 4.1R, 4.1N and 4.1G are detectable
in mouse ventricular cardiomyocytes [55,80,83]. They show discreet
subcellular locations.
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the lateral edge and at intercalated discs, and in cross-striations coinci-
dent with transverse tubules [55,80,83]. At intercalated discs, there
is signiﬁcant colocalization with components of the Ca2+-clearance
system: the Na+/Ca2+-exchanger NCX1 and the α-subunit of the Na+,
K+-ATPase [83]. At these sites, 4.1R seems to deﬁne a structural com-
partment distinct from known cell adhesion regions. It does not localise
with themajor points of cell adhesion, i.e. the cadherin-based structures
or gap junctions [83]. Since there is also no evidence from electron
microscopy of 4.1R-deﬁcient cardiomyocytes having any form of cell
adhesion defect [80], the localisation of 4.1R is consistent with a role
in organizing signalling systems, rather than cell adhesion.
Given the phenotype of the 4.1R knockout mouse (Section 4.1.2 –
elongated action potential and QT interval as well as alterations
in Na+/Ca2+ exchange current and persistent sodium current) the dis-
crete location of 4.1Rwith both the sodiumpumpand theNa+/Ca2+ ex-
changer potentially indicates the existence of a membrane domain in
intercalated discs in which 4.1R participates in coordinating Na+-based
signalling systems (summarized in Fig. 3). Such a domain would
probably contain spectrin since spectrin is present at these points
[116]. Furthermore, it is almost certainly similar to regions identiﬁed
by Mohler and co-workers as containing ankyrinG and the voltage
gated sodium channel, NaV1.5 [117]. In cardiomyocytes from the 4.1R
knockout mice approximately 40% of NaV1.5 is lost [80]. It is likely
that the remainder is linked to proteins such as ankyrin [118], and so
remain captured at the cell surface. The overlapping spectrum of 4.1
and ankyrin binding proteins is discussed in Section 9.
Like 4.1R, 4.1N is present in intercalated discs, but unlike 4.1R, it is
not localised at the lateral plasma membrane. Both 4.1R and 4.1N are
in internal structures that are most probably T-tubules. 4.1G is also in
intracellular structures, some of which are coincident with sarco-
plasmic reticulum. 4.1G exists in an immunoprecipitable complex
with spectrin and SERCA2 (Fig. 3) [83].
5.3. Other non-erythroid cells
Wider evidence for a role of 4.1R in membrane trafﬁcking comes
from studies on embryonic ﬁbroblasts in the 4.1R KO mouse [85].
In these, the trafﬁcking of βI-integrin is compromised, resulting in
lower integrin cell-surface expression and correspondingly reduced
motility of the cells into a wound [85]. It is also worth noting here
that 4.1R has been identiﬁed in high throughput interaction screens
as interacting with numerous components of trafﬁcking complexes
(Fig. 4).
The theme of 4.1 proteins being required for efﬁcient cell surface
expression of membrane proteins is recapitulated in the other three
paralogues.
5.3.1. GPCRs
In the case of G-protein coupled receptors (GPCR or 7 helical
receptors), several are known to have their cell surface localisation
modulated by one or other 4.1 protein. We have already mentioned
Duffy in relation to 4.1R. D2 and D3 dopamine receptors bind to 4.1N
[119]; mGluR1α [120], Adenosine A1 receptor [121] and Parathyroid
hormone (PTH)/PTH-related protein receptor (PTHR) [122] bind to
4.1G. In general, the interaction promotes cell surface expression and
ligand binding/signalling activity. However in the case of Adenosine
A1 receptor, the interaction gave a negative modulation with a higher
proportion of the receptor being retained internally [121].
5.3.2. Ligand-gated channels and formation of targeted complexes
Several ligand-gated receptors also bind to 4.1 paralogues. GluR1
and GluR3 bind 4.1N, and this increases their cell-surface expres-
sion [34,35]. 4.1N is required for GluR1 activity dependent on insertion
into the plasma membrane [123]. Similarly, the NMDA receptor binds
4.1B [124].The synaptic cell adhesion molecule 1 (SynCAM 1) interacts
with both 4.1N and 4.1B, and this provides an example of the cross-
linking function of 4.1 proteins [124]. 4.1B speciﬁcally interacts with
both SynCAM1 and NR1/NR2b NMDA-type glutamate receptors. In
transfected cell systems, 4.1B speciﬁcally recruits NMDA receptors
to sites of cell adhesion speciﬁed by SynCAM1. It also enhances
synaptogenic properties of SynCAM1 in in vitro culture systems,
and this requires the FERM domain. 4.1N interacts with AMPA-type
GluR1, as well as SynCAM1, and likewise targets GluR1 to SynCAM1-
mediated sites of cell adhesion. However, the results from these in
vitro cell culture experiments have been challenged by results from
mice with severe knockdown of 4.1N and 4.1G [125]. Although they
retain only very minor amounts of 4.1N and 4.1G they show no major
alteration to the function of glutamatergic synapses.Whether the residual
expression of 4.1N is sufﬁcient to allow function, or whether the
remaining 4.1 proteins (4.1R and 4.1B) can compensate for the loss of
4.1G and 4.1N remains to be determined.
Inositol tris phosphate(IP3) receptors seem to be tissue-speciﬁc in
their interaction with 4.1N. Several accounts demonstrate interaction
in nervous tissue [126–129]. In epithelia, the situation is more
complex: WIF-B cells epithelial IP3 receptors apparently do not interact
[130], but 4.1N is required for translocation of type 1 IP3 receptors to the
basolateral membrane domain in polarized MDCK cells [131].
5.3.3. Other channels
5.3.3.1. Store-operated channel. In endothelia, TRPC4 has been reported
to interact with 4.1 [132]. Deletion of part of the C-terminal cytoplas-
mic domain that contains a sequence resembling a 4.1-binding motif
leads to alterations in the inactivation characteristics of this channel.
5.3.3.2. Ion co-transporter. KCC2 mediates electroneutral K+-Cl−
co-transport in mature neurons. KCC2 has also been reported to func-
tion in correct maturation of spiny excitatory synapses on cortical
pyramidal neurons, independent of its transport activity [133]. This
function is linked to binding of its C-terminal domain to the FERM
domain of 4.1N. Intriguingly, since the CTD of 4.1N also binds AMPA
receptors, the potential exists for 4.1N to cross-link KCC2 and AMPA
receptor in a single complex duringmaturation of postsynaptic mech-
anisms (see [134] for further discussion).
5.4. Three-way complexes with PDZ/membrane-associated
guanylate kinases
Analysis of protein 4.1R deﬁcient human and mouse red cells
revealed that it was not just transmembrane proteins that were
lost; a palmitoylated protein known as p55 (MPP1) was also lost
from the cells [76]. p55 is a member of a family of proteins known
as membrane-associated guanylate kinases (MAGUK). These are also
adapter proteins, and they are characterised by PDZ, SH3 and
guanylate kinase-like domains. 4.1R binds to at least some of these
via a differentially spliced region known as I3 [135,136].
p55 also binds to the C terminus of glycophorin C via its PDZ
domain; thus 4.1R, p55 and glycophorin C form a three-way (ternary)
complex [76,137–139]. The precise signiﬁcance of this interaction
is not yet clear in erythrocytes, but presumably serves to control the
dynamics of the retention of glycophorin C (and potentially other
proteins) at the plasma membrane.
4.1R has been reported to interact with other MAGUK proteins
such as ZO-2, a tight junction protein [140] and HLDG/SAP-97 [135],
interactions that seem to mediate targeting to lateral membranes of
epithelial cells [136].
Examples exist of all four vertebrate 4.1 proteins forming analo-
gous ternary complexes with a MAGUK protein and a transmembrane
protein.
Fig. 3. Diagram of part of an intercalated disc (ID) at the junction between two cardiomyocytes showing two different types of domains associated with 4.1 proteins. The ID
membrane is heavily folded. Along part of the fold is the heavy plaque of the adherens junctions to which the thin ﬁlaments coming from the myoﬁbrils are associated. In plaque
free regions of the membrane, particularly at the tops of the folds, protein 4.1R [83] and spectrin [116] are found along with a number of signalling proteins such as Na+,K+-ATPase
and NCX1 [83]. Away from the ID where the SR meets the Z-disc, a domain containing 4.1G and SERCA is found [83].
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ternary complex with the sodium bicarbonate exchanger NBC1 [141].
4.1N forms a ternary complex with AMPA-type glutamate recep-
tors and SAP-97/HDLG, at least in certain sites in the nervous system
[142,143]. This seems to be the descendant of an ancient animal
complex, since the fruit ﬂy glutamate receptor GLURIIA is clustered
by the Drosophila 4.1 coracle [36]. Since, as noted above, 4.1N and
AMPA receptors also interact with SynCAM1, it seems highly likely
that this actually is a quaternary 4.1N-AMPAR-SAP97-SynCAM1 com-
plex [124]. Similarly, there are suggestions that the corresponding
complex for NMDA receptors may be 4.1B-NMDA-CASK-SynCAM1
[124]. Additionally, the twoMAGUKs CASK and SAP-97/HDLG interact
with each other [144] and appear to mediate trafﬁcking of at least one
voltage-gated ion channel [145] as well as sorting of NMDA receptors
[146]; the potential for cross-talk and targeting between different
4.1-MAGUK complexes becomes very large.
Protein 4.1G is required for the MAGUK MPP6 interactions in axons
[147]. In T-cells 4.1G and HDLG form a three-way complex with PTA-1
[148]. PTA-1 is a raft-associated lymphocyte type 1 transmembrane
protein which binds the 4.1G CTD. Upon T cell stimulation with
phorbol ester or PTA-1 cross-linking, PTA-1 can bind to the FERM
domain of 4.1G, and together with HDLG becomes tightly associated
with the cytoskeleton. PTA-1 is also associated with the integrin
LFA-1, and it is possible that the three-way 4.1G/HDLG/PTA-1 com-
plex provides a regulated mechanism for controlling the dynamics
of LFA-1.
In summary, then, the 4.1-MAGUK proteins interact to form three-
or four-way complexeswithmembrane proteins that have the potential
to target diverse membrane proteins to sites speciﬁed by cell adhesion
molecules. Since the MAGUKs themselves can interact with each other,
the potential exists for 4.1-MAGUK complexes to assemble large com-
plexes in dynamically regulated arrays.6. 4.1 and modulation of phosphorylation signalling
There are two primary examples where altered phosphorylation
results from changes in 4.1 expression.
In the 4.1R knockout mouse, the linker of activated T cells (LAT) is
hyperphosphorylated [142]. Regulation of phosphorylation of LAT
seems to require direct interaction of 4.1R with LAT, 4.1R apparently
acting as a negative regulator of this process.
In the analyses of the dynamics of PTHR, it was discovered that 4.1G
modulates phosphorylation in response to forskolin. 4.1G was found to
suppress adenylyl cyclase-mediated cAMPproduction [149]. The conse-
quences of this in relation tomodulation of signalling pathways remain
an interesting prospect of the future. For example, in the 4.1R knockout
mouse, 4.1G expression in heart is increased [80]. Are there conse-
quently alterations in phosphorylation events in 4.1R knockout mice?
What are the functional consequences in 4.1G knockouts?7. The question of speciﬁcity. Binding motifs on membrane
protein partners
In each of the cases of the major erythrocyte binding partners, the
cytoplasmic domain of the relevant membrane protein binds to one
of the three lobes of the FERM domain (see text above, Section 3).
In all cases, the interaction appears to be very speciﬁc by normal
biochemical criteria.
4.1R binds to the cytoplasmic domain of the erythrocyte anion
exchanger, band 3. The interaction is via a short sequence in lobe A
of the FERM domain, LEEDY [150] to a sequence I/LRRY in Band 3.
The interaction appears to be essential for erythropoeisis in zebraﬁsh
sincemutation in the Band 3 sequence results in binuclearity and failure
of chromosome segregation and cytokinesis [151].
Fig. 4. EBP41 protein interaction network. The human EBP41 protein interaction dataset was extracted from databases, including IntAct [159], MINT [188] and DIP [189], and
visualised using Cytoscape [190]. Each node in the network represents a ﬁrst-neighbour interaction partner protein of EBP41 (red-coloured node). Different isoforms of a gene
are shown as one node. The proteins, which are annotated with the GO term [191] GO:0016021 “Integral to membrane”, are coloured in green, whereas the proteins with orange
colour-code are cytoskeletal partners of 4.1R.
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C, a type I membrane protein [10,22]. Comparison of the sequences of a
number of type 1membrane proteins led to the suggestion of a common
motif RXKX0-4GXYX3E recognised by lobe B of the FERM domain that
is present in glycophorin C and the Neurexin family of cell adhesion
molecules [152]. NMR has revealed the pattern of interactive residues
on lobe B that stretch across the lobe (Fig. 1B,C) [22].
Further analysis revealed that there was a three-way interaction
with the MAGUK protein p55. In this complex, the PDZ domain of p55
also interacts with the C terminus of glycophorin C [139,153,154], and
the FERM domain binds to a differentially spliced I3 region in p 55
[137,139]. There are similar interactions with the domain in other
MAGUK proteins (for example, mammalian SAP97/hDLG or discs large
in fruit ﬂies) [136,155].
The interaction of lobe C with CD44 reveals a requirement for
a pattern of basic juxtamembrane residues [23]. Similar residues are
required for the interaction of lobe C of 4.1B with TSLC1 as shown
by x-ray crystallography [19].8. 4.1 proteins as hubs for protein and phospholipid interaction
Many biological processes are modulated or organized via direct
protein–protein interactions. A common analogy for the organization
of interacting networks is that they are like wheels with many
interacting partners on the rim, making interacting spokes that link
to a hub. Since the wheel will cease to function if the hub is lost
(unlike the loss of a single spoke) it is often thought that proteins
that represent hubs would be essential [see e.g. 156–158].
In general terms, hub proteins are often thought of as having large
numbers of interactions, they are essential in genetic analyses of
model organisms, are co-expressed with their partners, and are
frequently the target of regulation, especially by post-translational
modiﬁcation.
A further conceptual consideration is that hub proteins may or may
not interact with all their partners simultaneously. In this sense, hubs
can be divided into “party hubs” and “date hubs” [156]. A party hub
would be able to interact with multiple partners simultaneously; date
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organization.
Can the 4.1 proteins be considered as hubs? The fruitﬂy 4.1
protein, coracle, is an essential gene. It is recessive embryonic lethal
with defects in dorsal closure. By comparison, no loss of a single
vertebrate 4.1 protein seems to be embryonic lethal. However, since
the four vertebrate paralogues evolved from a single invertebrate
ancestor, it is likely that the functions of the ancestral protein were
distributed among its vertebrate descendants. As yet, there is no
published account of a quadruple knockout of all four mouse 4.1
genes: given the range of phenotypes the individual knockouts display,
it might be predicted that the quadruple knockout would be lethal.
Assessing the range of interactions of the 4.1 proteins in vertebrates
is still limited. As indicated in both Table 3 and Fig. 4, 4.1R interactswith
multiple transmembrane proteins, as well as the cytoskeletal proteins
spectrin, actin and tropomyosin simultaneously; the phospholipids
PIP2 and phosphatidylserine also interact simultaneously and at distinct
binding sites within 4.1R. In this sense, it fulﬁls the concept of a ‘party’
hub.
4.1R also fulﬁls a prediction that hubs are tightly regulated: as
we note above, the FERM domain is the target of regulation via
phosphorylation [28,29], binding of the lipid PIP2 [27], differential
splicing of the headpiece [31] and binding of calmodulin [23].
4.1R is not expressed only in erythrocytes: in the case of the heart,
the existence of a Na+-linked signalling complex in the intercalated disc
as we describe in Section 5.2 and Fig. 3 suggests that there is a separate,
although mechanistically related, 4.1R hub there that would connect the
cytoskeleton to a different range of transmembrane proteins.
Beyond these interactions, interaction databases such as IntAct
[159] document results from high throughput protein interaction
screens. Remarkably, the interaction databases document more than
100 further interactions for 4.1R (Fig. 4). Given the range of tissues
that express 4.1R, one might conceptualise it as a multi-party hub.
Since the study of 4.1N, 4.1G and 4.1B is still not as advanced as
that of 4.1R, we may anticipate the discovery of numerous further
interactions of these proteins. Nevertheless, in considering 4.1N and
4.1B in the nervous system, it is notable that AMPA and NMDA receptor
organization in relation to sites of cell adhesion seems to revolve around
complexes of 4.1N and 4.1B (see Section 5.3).
9. 4.1 and ankyrin: common and distinct transmembrane partners
Among the transmembrane proteins that bind to 4.1, several also
bind to another cytoskeletal adaptor, ankyrin. Like 4.1, ankyrin binds
spectrin, and it too emerged as an adaptation of early eumetazoa
[52,160]. A separate spectrin-linked complex exists based around
ankyrin (Fig. 1A). This has been conceptualized as a metabolon for
CO2 transport [161]. It contains (among other proteins) the Rh/RhAG
complex, small molecule transporters that appear to mediate part of
the CO2 transport capacity of red cells. It also contains the anion ex-
changer, band 3, which catalyses electroneutral exchange of HCO3−
ions (i.e. dissolved CO2) for Cl−. Both the Rh and Band 3 bind 4.1R and
ankyrin, as does CD44. In general, it seems likely that there are discrete
binding sites for ankyrin and 4.1. This has been demonstrated for both
band 3 and CD44 [162,163].
An emerging topic of interest is the relationship of 4.1 to Na+-linked
signalling. Fruitﬂy 4.1 (coracle), as we note in Section 4.1.4, has a
functional relationship with the Na+, K+-ATPase [111]. In mammalian
heart, 4.1R overlaps in distribution with the Na+, K+-ATPase and
NCX1 [83]. AnkyrinB, too, overlaps with and binds both these proteins,
as well as IP3 receptor, another 4.1 binding protein [164–166].
Why would it be advantageous for individual proteins to bind
both 4.1 and ankyrin? One possibility is that 4.1 proteins and ankyrins
are differentially regulated. 4.1R binds PIP2 in the FERM domain, and
this regulates the interaction with transmembrane partners [27], but
apparently not ankyrin. In this case, PIP2, acting via 4.1, would be able toexert an effect on the regulatory properties of a channel/transporter,
while ankyrin would remain unchanged as a cytoskeletal tether. An al-
ternative hypothesis might be that ankyrin and 4.1R recognize different
states of the target proteins. For example, ankyrin binds band 3 tetra-
mers in red cells, and stoichiometrically, this seems to account for bind-
ing of all the tetramers [167]. The remaining band 3 population is
presumably dimeric, so it seems likely that ankyrin and 4.1 discriminate
between self-association states of the same protein [24]. Finally, both
proteins have the potential to be cross-linkers, and bind more than
one protein simultaneously. Ankyrin and 4.1 could assemble discrete
mixtures containing some common proteins into functionally distinct
complexes which could be targeted to different sites of cell adhesion.
For example, ankyrin binds neurofascin family cell adhesion molecules
[168], while 4.1 binds others such as neurexin family and SynCAM1.10. Conclusions and perspectives
The 4.1 proteins are a remarkable group of paralogous proteins
in vertebrates, whose functions are a long way from being fully under-
stood. They emergedwith eumetazoa, and, since then, conserved FERM
and CTD regions appear to have retained interactions with various cell
adhesion and transporter proteins giving them the potential to position
transmembrane signalling complexes at sites speciﬁed by activated cell
adhesion molecules.
The shear breadth of the interactions of these proteins means
that characterization of knockout mice is far from straightforward,
with different phenotypes being revealed in different tissues and
at different developmental stages. Complicating factors include the
overlapping spectrum of interactions of each 4.1 protein, meaning
that phenotypes resulting from any individual protein 4.1 gene
knockout may be masked by compensation by a different 4.1 protein
gene.
We also highlight two emerging areas of future interest. A major
question arises as to the relationship of 4.1 proteins to the ion channel
signalling systems in heart. Energy captured in the Na+ gradient
across cardiomyocyte plasma membranes drives the channels and
exchangers that underpin the signalling that controls the regular
beating of the heart. As yet, although there are functional and spatial
correlations between 4.1R and some of the key cardiac proteins (Na+,
K+-ATPase, NaV1.5 and NCX1 among others) no molecular basis
for this has been published. Likewise, ankyrin is known to bind each
of these. Deﬁning the full role of 4.1 proteins in a “4.1 Na+ hub” and
its relationship to a hypothetical “ankyrin Na+ hub” is a challenge
for the future.
The other issue is that additional aspects of 4.1 function are hinted
at from the interactions databases. Fig. 4 shows the 4.1 interactions
identiﬁed in a combination of high throughput interactome analyses
as well as text mining from the peer-reviewed literature. The high
throughput data (with all its limitations) reveal numerous inter-
actions not properly developed yet in the literature, but which ﬁt
with known aspects of function. There are, for example trafﬁcking
defects in 4.1R knockout ﬁbroblasts that reduce βI-integrin at the cell
surface [85]. Similarly, 4.1B and 4.1G regulate integrin-dependent
spreading of astrocytes [169], and an isoform of 4.1B functions within
the Golgi [170]. Numerous trafﬁcking/sorting proteins are noted in the
interaction analysis (Fig. 4). Spreading andmotility, aswell asmetastatic
processes (most closely linked to 4.1B), all require small G proteins of
the ras family (rho/rac and others): elements of these pathways too
are found in the interaction analysis (Fig. 4). The relationship between
4.1 proteins and rho/rac signalling remains to be investigated.Disclosures
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